| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
4000862158 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:Rintodestrant
CAS:2088518-51-6
Purity:>=99% Package:10mg;100mg;10mM*1mLinDMSO;5mg;50mg
|
| Company Name: |
RD International Technology Co., Limited
|
| Tel: |
18024082417 |
| Email: |
market@ubiochem.com |
| Products Intro: |
Product Name:Atuveciclib Racemate
CAS:2088518-51-6
Purity:5mg;10mg;50mg;100mg;250mg;500mg;1g Package:5mg;10mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
Qingdao Haizhi Weiyuan Biotechnology Co., Ltd.
|
| Tel: |
18317699790 18317699790 |
| Email: |
l202008112023@163.com |
| Products Intro: |
Product Name:(2E)-3-[4-[[2-(4-Fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-2-propenoic acid (ACI)
CAS:2088518-51-6
Purity:98% Package:1g;5g;25g;100g;250g;500g;1Kg;2Kg;5Kg;10Kg;25Kg;100Kg;500Kg
|
| Company Name: |
Guangzhou Ruidi Biotechnology Co., Ltd.
|
| Tel: |
020-82099279 18988941402 |
| Email: |
sales@ubiochem.com |
| Products Intro: |
Product Name:Atuveciclib Racemate
CAS:2088518-51-6
Purity:0.98 Package:5mg;10mg;25mg;50mg;100mg
|
|
| | 2-Propenoic acid, 3-[4-[[2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-, (2E)- Basic information |
| | 2-Propenoic acid, 3-[4-[[2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-, (2E)- Chemical Properties |
| Boiling point | 649.9±55.0 °C(Predicted) | | density | 1.390±0.06 g/cm3(Predicted) | | form | Solid | | pka | 4.45±0.10(Predicted) | | color | Light yellow to green yellow |
| | 2-Propenoic acid, 3-[4-[[2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-, (2E)- Usage And Synthesis |
| Uses | Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor[1]. | | in vivo | Rintodestrant (G1T48, 30 or 100 mg/kg) inhibits estrogen signaling in endocrine-resistant breast cancer models[1].
| Animal Model: | MCF7 xenograft tumors[1]. | | Dosage: | 30 or 100 mg/kg. | | Administration: | P.O. daily for 28 days. | | Result: | Demonstrated dose-dependent inhibition of TamR tumor growth. |
| | References | [1] Kaitlyn J Andreano, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646. DOI:10.1007/s10549-020-05575-9 |
| | 2-Propenoic acid, 3-[4-[[2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thien-3-yl]oxy]phenyl]-, (2E)- Preparation Products And Raw materials |
|